Serum Alpha-Synuclein Levels Are Decreased in Patients with Restless Legs Syndrome and Restored by Intravenous Iron Therapy in Correlation with Ferritin
Objective: To determine potential connection between serum Alpha-synuclein (α-syn) concentrations and restless legs syndrome (RLS), and explore the impact of intravenous (IV) iron supplementation on serum…New α-Synuclein Strain Biomarker in Parkinson’s Disease and Related Dementia
Objective: Biomarker development for Parkinson’s disease and related dementia. Background: α-Synuclein (α-syn) strains can serve as discriminators of Parkinson's disease (PD) from other α-synucleinopathies. However,…The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.
Objective: Understanding the biological link between alpha-synuclein biomarker changes and clinical outcome using computer simulation. Background: A number of disease modifying therapeutic interventions focused on…Exploring the Therapeutic Target for Lewy Body Disease using gba1 Knock-out Medaka
Objective: This study was performed to explore the therapeutic target for Lewy body disease. Background: Lewy body disease (LBD), including Parkinson's disease and diffuse Lewy…Prevalence of Phosphorylated Alpha-Synuclein in Skin Biopsies of Essential Tremor Patients
Objective: To examine the prevalence of phosphorylated alpha-synuclein in nerve fibers in patients with essential tremor (ET) and ET plus. Background: Although Essential Tremor (ET)…Visual Hallucinations and α-Synuclein Oligomers in Dementia with Lewy Bodies (DLB)
Objective: To determine whether visual hallucinations (VH) in dementia with Lewy bodies (DLB) are associated with α-synuclein oligomers. Background: It is not known whether VH…Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein
Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…Interaction of GCase and ganglioside GM1 in the aggregation of α-Synuclein
Objective: The objective of this work is to investigate the relationship between ganglioside GM1 levels and α-synuclein aggregation in the context of GBA1 mutations. Background:…Parkinson’s disease associated SORL1 variants impair mitochondrial and endo-lysosomal function
Objective: We investigate the relationship between Sortilin-related receptor (SORL1) gene and PD, along with their functional implications. Background: Parkinson's disease (PD) is a common neurodegenerative…A Phase 2 Study of ATH434 a Novel Inhibitor of α-Synuclein Aggregation for the Treatment of Multiple System Atrophy
Objective: Describe baseline fluid and neuroimaging biomarker data of an early MSA study population Background: MSA is a rapidly progressive neurodegenerative disorder characterized by aggregated…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 51
- Next Page »